Cameroon

Section divider

Helping to keep families healthy and free from malaria since the mid-1980s.

  • From 2016 to 2019, more than 24,000 cases of malaria were confirmed by testing and then treated using artemisinin-based combination therapy, as recommended by the World Health Organization. In 2019, community health volunteers tested 94% of patients with a fever for malaria; of these, 87% were confirmed positive for malaria and 84.6% received treatment.
  • Also from 2016 to 2019, more than 25,000 pregnant women received intermittent preventive treatment for malaria (IPT) under direct observation—thereby receiving protection from the dangers of malaria in pregnancy. The rate for a first dose of IPT increased from 70% in 2012 to 86% in 2019 and the rate for a second dose increased from 61% in 2012 to 59% in 2019, compared to a national average of 84% and 66%, respectively. This data show that the areas covered by Jhpiego’s projects are achieving higher rates than the rest of the country.
  • The percentage of cases of malaria at Jhpiego-supported sites treated according to Cameroon’s national guidelines increased from 70% in 2012 to 93% in 2019.
  • From 2016 to 2017, Jhpiego strengthened the Ministry of Health’s ability to respond to epidemics by supporting development of national infection prevention and control (IPC) guidelines, training a pool of national IPC trainers and three Ebola Rapid Response Teams, and strengthening the capacity of more than 90 providers from 77 health facilities in Kribi, Lolodorf and Ebolowa districts via IPC training and donation of essential IPC equipment.

Our Work in Cameroon

Malaria is the leading cause of morbidity and mortality in Chad and Cameroon, and is particularly dangerous for children and pregnant women. With support from ExxonMobil, Jhpiego is strengthening the capacity of the Chadian and Cameroonian Ministries of Health, the National Malaria Control Programs, health providers and community health volunteers to provide high-quality malaria prevention and treatment for nearly 1,180,000 people living in ten malaria-endemic districts along ExxonMobil’s 1,070-kilometer pipeline. The nine districts are Doba, Bodo, Béboto, Bébédjia, Goré, Bessao, Laramanaye, Donia, Kara (in Chad), and Kribi (in Cameroon). In addition to leading the development of national-level malaria guidelines, training manuals and reference materials, Jhpiego has trained health providers, supervisors and community health volunteers to provide health services and/or health messages. These interventions have resulted in provision of lifesaving treatment to people with confirmed cased of malaria and improved coverage for intermittent preventive treatment of malaria among pregnant women.

Impact Malaria is a global project of the U.S. President’s Malaria Initiative to reduce mortality and morbidity caused by malaria. Implemented by a consortium of organizations led by PSI, the project is funded by the U.S. Agency for International Development. In close collaboration with the National Malaria Control Program, other sections of the Ministry of Health and various implementing partners, Impact Malaria is designed to improve malaria service delivery via the following objectives: 1) improve the quality of and access to malaria case management and prevention of malaria in pregnancy; 2) improve the quality of and access to other malaria drug-based approaches and provide support to pilot/scale up newer malaria drug-based approaches; and 3) provide global technical leadership, support operational research and advance program learning. In Cameroon, Impact Malaria supports PMI’s focus on expanding and improving the quality of malaria case management and prevention in 300 facilities in 18 districts in the North and Far North regions.

RISE is a five-year global project funded by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) and the U.S. Agency for International Development (USAID). RISE works with countries to achieve a shared vision of attaining and maintaining epidemic control, with stronger local partners capable of managing and achieving results through sustainable, self-reliant and resilient health systems by 2024. RISE’s contributions to this work will lead to fewer new HIV infections, decreased HIV-related morbidity and mortality, and increased quality of life for people living with HIV. With USAID PEPFAR investments, RISE supports countries to achieve and maintain epidemic control by providing strategic technical assistance and direct service delivery to improve HIV prevention, case finding, treatment programming, and viral load suppression. The primary objectives of the RISE project are to: 1) attain and maintain HIV epidemic control among at-risk adult men, women and priority populations; 2) attain and maintain HIV epidemic control among key populations; 3) strengthen health systems including improved program management, health information systems, human resources for health and financial systems to ensure attainment and maintenance of epidemic control; and 4) support the transition of direct funding and implementation to capable local partners to meet the PEPFAR goal of 70% of funding to local partners by 2020. The project is led by Jhpiego with the following partners: ICAP at Columbia University, Management Sciences for Health, Anova, BAO Systems, Johns Hopkins University Center for Public Health and Human Rights, and Mann Global Health. RISE is currently active in several countries, including Cameroon.